A statistical model for the dependence between progression-free survival and overall survival

被引:58
作者
Fleischer, Frank [1 ]
Gaschler-Markefski, Birgit [1 ]
Bluhmki, Erich [1 ]
机构
[1] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany
关键词
oncology; progression-free survival; overall survival; surrogate endpoint; dependence; statistical modelling; END-POINTS; TRIALS; SURROGATE; AGENTS;
D O I
10.1002/sim.3637
中图分类号
Q [生物科学];
学科分类号
090105 [作物生产系统与生态工程];
摘要
Among the surrogate endpoints for overall survival (OS) in oncology trials, progression-free survival (PFS) is more and more taking the leading role. Although there have been some empirical investigations on the dependence structure between OS and PFS (in particular between the median OS and the median PFS), statistical models are almost non-existing. This paper aims at filling this gap by introducing an easy-to-handle model based on exponential time-to-event distributions that describe the dependence structure between OS and PFS. Based on this model, explicit formulae for individual correlations are derived together with a lower bound for the correlation of OS and PFS which is given by the fraction of the two medians for OS and PFS. Two methods on how to estimate the parameter of the model froth real data are discussed. One method is based on a maximum-likelihood estimator whereas the other method uses a plug-in approach. Three examples from non-small cell lung cancer are considered. In the first example, the parameters of the model are determined and the estimated survival curce is compared with the observed one. The second example explains how to obtain sample size estimates for OS based on assumptions on median PFS and OS. Finally, the third example provides a way of modelling and quantifying confounding effects that might explain a levelling of differences in OS although a difference in PFS is observed. Copyright (C) 2009 John Wiley & Sons, Ltd.
引用
收藏
页码:2669 / 2686
页数:18
相关论文
共 24 条
[1]
[Anonymous], 2003, Modelling Survival Data in Medical Research
[2]
[Anonymous], MULT S THOR ONC CHIC
[3]
GRAPHS IN STATISTICAL-ANALYSIS [J].
ANSCOMBE, FJ .
AMERICAN STATISTICIAN, 1973, 27 (01) :17-21
[4]
A STUDY OF THE USE OF THE PROBABILITY-OF-BEING-IN-RESPONSE FUNCTION AS A SUMMARY OF TUMOR RESPONSE DATA [J].
BEGG, CB ;
LARSON, M .
BIOMETRICS, 1982, 38 (01) :59-66
[5]
Progression-free survival is a surrogate for survival in advanced colorectal cancer [J].
Buyse, Marc ;
Burzykowski, Tomasz ;
Carroll, Kevin ;
Michiels, Stefan ;
Sargent, Daniel J. ;
Miller, Langdon L. ;
Elfring, Gary L. ;
Pignon, Jean-Pierre ;
Piedbois, Pascal .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (33) :5218-5224
[6]
Analysis of progression-free survival in oncology trials: Some common statistical issues [J].
Carroll, Kevin J. .
PHARMACEUTICAL STATISTICS, 2007, 6 (02) :99-113
[7]
Inference for multi-state models from interval-censored data [J].
Commenges, D .
STATISTICAL METHODS IN MEDICAL RESEARCH, 2002, 11 (02) :167-182
[8]
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].
Eisenhauer, E. A. ;
Therasse, P. ;
Bogaerts, J. ;
Schwartz, L. H. ;
Sargent, D. ;
Ford, R. ;
Dancey, J. ;
Arbuck, S. ;
Gwyther, S. ;
Mooney, M. ;
Rubinstein, L. ;
Shankar, L. ;
Dodd, L. ;
Kaplan, R. ;
Lacombe, D. ;
Verweij, J. .
EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247
[9]
Analysis of duration of response in oncology trials [J].
Ellis, Stuart ;
Carroll, Kevin J. ;
Pemberton, Kristine .
CONTEMPORARY CLINICAL TRIALS, 2008, 29 (04) :456-465
[10]
Clinical studies in the development of new anticancer agents exhibiting growth inhibition in models: facing the challenge of a proper study design [J].
Eskens, FALM ;
Verweij, J .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2000, 34 (02) :83-88